Vaccine Trials T Cell Response HIV Vaccines Intranasal Vaccination Tumour-Associated Antigens HIV Immunology mRNA Vaccines Clinical Trials mRNA Technology
Harnessing aluminum hydroxide alongside a saponin nanoparticle to sustain antigen retention for up to a month, the vaccine primes diverse B cell responses ahead of clinical trials.